By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Phoenix RelationsPhoenix RelationsPhoenix Relations
  • Home
  • Categories
    • CrimeUnlimited
    • Economy
    • Education
    • Entertainment
    • HealthHot
    • Exclusives
    • News100+
    • Politics
    • Press Realeases
    • Sports
    • Tech
    • Opinions
  • About
  • Privacy Policy
  • Contact Us
Reading: Pfizer To Acquire Obesity-Drug Maker Metsera For $4.9bn
Share
Sign In
Notification Show More
Font ResizerAa
Phoenix RelationsPhoenix Relations
Font ResizerAa
Search
  • Home
  • About Us
  • Blog
  • Categories
    • Crime
    • Economy
    • Education
    • Entertainment
    • Health
    • Exclusives
    • News
    • Politics
    • Press Realeases
    • Sports
    • Tech
    • Opinions
  • Contact
  • Privacy Policy
Have an existing account? Sign In
Follow US
  • Advertise
© 2024 Phoenix Relations. All Rights Reserved.
Economy

Pfizer To Acquire Obesity-Drug Maker Metsera For $4.9bn

Phoenix Relations
Last updated: 22 September 2025 13:44
Phoenix Relations
Share
2 Min Read
SHARE

US pharmaceutical giant Pfizer will acquire Metsera, a maker of drugs for obesity and heart disease, for $4.9 billion, the companies said Monday.

With the purchase, Pfizer aims to expand its portfolio by entering the huge and growing market for medicines to treat obesity.

“Obesity is a large and growing space with over 200 health conditions associated with it,” Pfizer CEO Albert Bourla said in the statement.

“The proposed acquisition of Metsera aligns with our focus on directing our investments to the most impactful opportunities and propels Pfizer into this key therapeutic area,” he said.

Pfizer will acquire all outstanding shares of Metsera common stock for $47.50 per share, in a deal expected to close in the final quarter of this year.

Pharmaceutical companies are eager to get into the obesity and diabetes medicine business following the success of Danish firm Novo Nordisk’s Ozempic and Wegovy drugs, and US giant Eli Lilly’s Zepbound.

 

Pfizer was one of the first companies to develop a Covid vaccine in a hugely profitable breakthrough, but its stock has fallen since the pandemic ended, from $58 a share in December 2021 to $24 a share at Friday’s close in New York.

In electronic trading before the opening of Wall Street on Monday, Pfizer was up 1.6 percent while Metsera soared by 60 percent.

 

AFP

You Might Also Like

Nigeria’s fintechs hit a cross-border wall

Tegbe: Nigeria Mobilises New Investment, Super Grid Plans as Power Sector Enters Next Reform Phase

AFRICA IS NOT AT THE MARGINS OF ENERGY GEOPOLITICS; IT IS THE FULCRUM — TEGBE

Ondo State Launches 1,000-Hectare Coffee Plantation to Boost Exports

Domestic refiners in Nigeria bypass $3.13 billion in crude oil acquisitions as pricing disputes escalate.

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Copy Link Print
Share
Previous Article Tinubu Has No Plans To Extend Tenure Beyond 2031, Presidency Replies El-Rufai
Next Article FG Constitutes Committee To Investigate DICON Explosion
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

//

We influence 20 million users and we are the number one  news network on the planet

Stay Connected

235.3kFollowersLike
69.1kFollowersFollow
11.6kFollowersPin
56.4kFollowersFollow
136kSubscribersSubscribe
4.4kFollowersFollow
- Advertisement -
Ad imageAd image

Latest News

Nvidia’s board is reportedly ‘not considering’ hiring Jensen
Default Blog 17 November 2026
EU Sanctions Pro-Russian Hacker Group and Propaganda Firm
Press Releases 17 November 2026
Lawyer on the microchip case passcode
Press Releases 17 November 2026
Power Minister Tegbe Reaffirms Tinubu Administration’s Commitment to Improved Electricity Supply
Press Releases 16 November 2026

Technology

  • Advertise with us
  • Terms & Conditions
  • Privacy Policy

Health

  • Advertise

Entertainment

Sign Up for Our Weeky Newsletter

Subscribe to our weekly newsletter to get our newest article/news/articles instantly!

Phoenix RelationsPhoenix Relations
Follow US
© 2024 Phoenix Relations. | All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?